Clinical Trial Update: A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update evaluating change in disease activity when subcutaneous epcoritamab is added to R-CHOP versus R-CHOP alone in adults with newly …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DOXORUBICIN HYDROCHLORIDE (Doxorubicin hydrochloride)
• Epcoritamab (epcoritamab)
• PREDNISONE (Prednisone)
• Rituximab (rituximab)
• Vincristine (vincristine)

Snippet

Sponsor: Genmab | Conditions: Diffuse Large B-Cell Lymphoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING